Antihypertensive Management — Zaib Un Nisa (67F, post-IVH)

Why the Current Regimen is Inadequate

• Prazosin (alpha-1 blocker) is not a first-line agent for hypertension in any major guideline (AHA/ACC, ESC, NICE). It lacks cardiovascular outcome data.
• It has no renoprotective benefit in CKD, no heart failure outcome benefit, and no specific post-stroke indication.
• Its short half-life causes significant BP variability, which is particularly dangerous post-ICH — BP variability independently worsens outcomes after intracerebral hemorrhage (Tanaka et al., Stroke 2014; de Havenon et al., Stroke 2018).
• BP of ~180/70 mmHg represents uncontrolled, isolated systolic hypertension — a major risk factor for recurrent hemorrhagic stroke.

BP Target for This Patient

Recommended Drug Strategy

1. ACE Inhibitor or ARB — FIRST PRIORITY

• Indications: CKD stage 4 (renoprotective, reduces proteinuria), DM2, HFpEF, hypertension, post-stroke
• Choice: Ramipril 2.5–5 mg OD OR Telmisartan 20–40 mg OD (if ACEi-intolerant)
• Caution: Monitor creatinine and K⁺ at 1–2 weeks; acceptable if creatinine rise <30% and K⁺ <5.5 mmol/L
• Note: Valsartan was held during admission due to AKI — check current eGFR before recommencing. If eGFR has stabilized, an ARB/ACEi should be restarted.

2. Calcium Channel Blocker (CCB) — ADD-ON

• Choice: Amlodipine 5 mg OD (titrate to 10 mg)
• Indications: Isolated systolic hypertension, post-stroke BP reduction, well-tolerated in CKD
• Has a long half-life — reduces BP variability (important post-ICH)
• Caution regarding aortic stenosis: CCBs are generally safe in aortic stenosis unless severe AS with low EF. She has HFpEF (preserved EF), so amlodipine is acceptable. Avoid verapamil/diltiazem due to negative inotropy + conduction effects.

3. Consider SGLT2 Inhibitor (for DM + HFpEF + CKD)

• Empagliflozin 10 mg OD or Dapagliflozin 10 mg OD
• Provides: HFpEF benefit (EMPEROR-Preserved, DELIVER trials), renal protection (EMPA-KIDNEY, DAPA-CKD), modest BP lowering (~3–5 mmHg SBP), cardiometabolic benefit
• Caution: eGFR must be ≥20 ml/min for dapagliflozin; ≥20 ml/min for empagliflozin. With CKD stage 4 (GFR 15–29), empagliflozin can still be used for its cardioprotective/renal effects even at lower eGFR — check current eGFR.
• Reduces recurrent CV events and hospitalizations in this phenotype.

4. Consider Low-dose Thiazide-like Diuretic or Loop Diuretic

• If she has fluid overload (HFpEF): Furosemide 20–40 mg OD
• Thiazide diuretics (e.g., indapamide 1.5 mg SR) are effective for isolated systolic hypertension and have post-stroke data (PROGRESS trial — perindopril + indapamide reduced recurrent stroke by 43%)
• However: In CKD stage 4, thiazides have reduced efficacy; loop diuretics preferred if diuresis is needed.

5. Discontinue or Deprioritize Prazosin

• Once effective agents are added and BP controlled, prazosin can be weaned off.
• If retained for any reason (e.g., urinary symptoms), it should not be the primary antihypertensive.

Practical Titration Sequence

Step 1 (Now):
- Restart ACEi/ARB if renal function allows (check BMP first)
  → Ramipril 2.5 mg OD or Telmisartan 20 mg OD
- Add Amlodipine 5 mg OD

Step 2 (2–4 weeks, if BP still >130/80):
- Up-titrate Amlodipine to 10 mg OD
- Up-titrate Ramipril to 5–10 mg OD / Telmisartan to 40–80 mg OD

Step 3 (If BP still not at target):
- Add Indapamide 1.5 mg SR OD (or furosemide if HF-related fluid overload)
- Introduce SGLT2i if eGFR permits

Step 4:
- Wean and discontinue prazosin

Special Considerations in This Patient

Monitoring Plan

• Week 1–2: Renal function (Cr, K⁺, eGFR) after starting/restarting ACEi/ARB
• Monthly: BP (home readings ideally), renal function, blood glucose/HbA1c
• Quarterly: BMP, lipid panel (she has hyperlipidemia — ensure statin is on board)
• Echocardiogram: Reassess severity of aortic stenosis and EF — guides further management

Summary

1. ACEi or ARB (renoprotection, post-stroke BP reduction, DM)
2. Long-acting CCB (amlodipine) for sustained BP control with minimal variability
3. SGLT2 inhibitor given the triple overlap of DM + HFpEF + CKD
4. Diuretic as needed
5. Target SBP <130 mmHg to prevent recurrent hemorrhagic stroke

Insulin Regimen Review & Optimization

Problem 1: The Regimen Makes No Pharmacological Sense

• Insulin lispro 12 U OD — lispro is a rapid-acting insulin (onset 15 min, peak 30–90 min, duration 2–4 hours). Giving it once daily provides no meaningful basal coverage. It is not a basal insulin and should never be used as one.
• "Short-acting TDS" — presumably regular insulin (Actrapid/Humulin R) three times daily, likely with meals.

Problem 2: What She Actually Needs

Recommended Revised Regimen

Step 1 — Start Basal Insulin

• Insulin glargine (Lantus) 10 U SC at bedtime (or 0.1–0.2 U/kg/day)
  • For a typical 60–70 kg woman: start at 10–14 U at night
  • Titrate by 2 U every 3 days if fasting glucose >7 mmol/L (>126 mg/dL)
  • Target fasting glucose: 5–8 mmol/L
• Alternatively: Insulin degludec (Tresiba) — preferred if hypoglycemia is a concern (longer, flatter profile)

Step 2 — Bolus Insulin with Meals

• Insulin lispro (or aspart) before each main meal — keep the TDS short-acting but clarify it is a rapid-acting analogue
• Starting dose: 4–6 U per meal, titrate based on 2-hour post-meal glucose
• Target post-prandial glucose: <10 mmol/L (180 mg/dL)
• Important: She is PEG-fed — bolus insulin should be given relative to tube feed timing, not "meals." If feeds are continuous, a basal-only or basal-heavy regimen may be more appropriate. If bolus feeds TDS, give rapid-acting insulin with each feed.

Step 3 — Discontinue the Single Daily Lispro

Add-on Non-Insulin Therapy

SGLT2 Inhibitor — Strongly Recommended

• Empagliflozin 10 mg OD — proven benefit in HFpEF (EMPEROR-Preserved) and CKD (EMPA-KIDNEY) even at low eGFR
• Reduces HbA1c by ~0.5–1%, lowers SBP by 3–5 mmHg, reduces hospitalization for HF
• Can be used down to eGFR ≥20 ml/min for cardio/renal indication (even if glycemic efficacy is reduced)
• Given via PEG tube (tablet dispersible in water)

DPP-4 Inhibitor — Alternative if SGLT2i not tolerated

• Linagliptin 5 mg OD — no dose adjustment needed in CKD (unlike sitagliptin/alogliptin)
• Safe in CKD stage 4, neutral on HF outcomes
• Modest HbA1c reduction (~0.5–0.8%)
• Per guidelines (Medications for Blood Glucose Management in T2DM): DPP-4i are second-choice behind SGLT2i/GLP-1 RA in patients with CKD and HF, but useful when those are contraindicated or unavailable.

Blood Glucose Targets for This Patient

Strict glycemic control is less important than avoiding hypoglycemia in this patient. Hypoglycemia post-stroke causes secondary neurological injury and worsens outcomes. A slightly relaxed HbA1c target of 7.5–8% is appropriate.

PEG Tube Feeding Considerations

• If on continuous feeds: use basal insulin only (glargine/degludec) + correction doses; avoid fixed-dose pre-meal bolus
• If on intermittent bolus feeds TDS: give rapid-acting insulin with each feed bolus
• Hold rapid-acting insulin if feed is delayed or stopped — risk of hypoglycemia
• Monitor glucose every 6 hours initially

Summary of Changes

Revised Assessment: Lantus (Glargine) 12 U OD + Lispro TDS

What She Has Now

Why 12 U Glargine is Likely Insufficient

• Standard basal insulin starting dose: 0.1–0.2 U/kg/day
  • At 65 kg: 6.5–13 U → 12 U is at the lower end of the starting range, not a therapeutic maintenance dose
• For uncontrolled T2DM already on basal-bolus, the basal requirement is typically 0.3–0.5 U/kg/day
  • At 65 kg: that's ~20–35 U of glargine
• 12 U is essentially a starting/initiation dose — it has likely never been titrated up

Basal Insulin Titration Protocol

• Review and adjust every 3 days
• No ceiling until fasting glucose is consistently at target (6–8 mmol/L)
• Most T2DM patients on basal-bolus end up needing 30–60 U/day of glargine

Bolus Lispro — What to Check

• Fixed low dose not titrated to meal size or post-prandial glucose
• Not being given appropriately relative to PEG feeds (as discussed previously)

The "Basal First" Diagnostic Step

Practical Plan

1. Titrate glargine upward — increase by 2–4 U every 3 days based on fasting glucose, targeting 6–8 mmol/L. Most patients will need 25–40 U before fasting glucose is controlled.
2. Check lispro dose — if not documented, start at 4–6 U per feed/meal and titrate by 2-hourly post-feed glucose.
3. Add Empagliflozin 10 mg OD — provides independent glycemic, cardiac, and renal benefit on top of insulin (check current eGFR first).
4. Monitor for hypoglycemia — especially important post-IVH; if any fasting glucose <5 mmol/L, reduce glargine before increasing it further.
5. HbA1c target: 7.5–8% — do not push for tight control given her neurological status and hypoglycemia risk.

Bottom Line